Fusion Pharma, a resident of the Skolkovo Foundation's Biomedical Technologies Cluster, signed a license agreement with Pharmasyntez to commercialize an innovative antileukemic drug

Fusion Pharma's abstract on PF-114 was selected for oral presentation on 60th ASH meeting

Fusion Pharma is to present interim results of the ongoing Phase 1/2 clinical study of PF-114 in CML patients

Fusion Pharma will participate in the BIO International Convention

Fusion Pharma is to participate at the Biotech Showcase, January 8-10, San Francisco, USA

Fusion Pharma's abstract on PF-114 was selected for oral presentation on 59th ASH meeting

PF-114 has been granted Orphan drug status in the US

Fusion Pharma will participate in the BIO International Convention